Nasdaq
$86.29▲ 0.45%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.26BShares out 1.100M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
44- 10.16After-hours26.10.17 07:244Ownership#●●●
CORCEPT THERAPEUTICS INC
Insider James N. Wilson of Corcept Therapeutics filed a Form 4 report regarding changes in beneficial ownership of securities as of October 15, 2026. This filing serves as a standard disclosure of insider equity transactions.…more
$86.29+0.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 08:584Ownership
CORCEPT THERAPEUTICS INC
Corcept Therapeutics insider Roberto Wandenkolk Vieira filed a Form 4 on October 5, 2026, reporting a change in beneficial ownership of securities as of October 2, 2026. This filing serves as an official disclosure of the insider's equity transaction.…more
$86.29+0.45%vs prev closeView filingShare - 10.5After-hours26.10.06 08:544Ownership
CORCEPT THERAPEUTICS INC
Insider Joseph Douglas Lyon of Corcept Therapeutics reported a change in beneficial ownership of securities effective October 1, 2026. This filing serves as an official disclosure of the insider's equity position change, reflecting standard regulatory reporting for corporate insiders.…more
$86.29+0.45%vs prev closeView filingShare
43 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoAfter-hours26.10.21 05:02#●●●#●●●
Corcept Therapeutics: ADA and EASD Recommend Hypercortisolism Screening in T2D Patients…more
Major diabetes associations now recommend screening for hypercortisolism in difficult-to-control type 2 diabetes patients, citing data from Corcept's CATALYST trial. This clinical validation supports the potential expansion of the company's therapeutic reach.…more
$86.29+0.45%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.18Pre-market26.09.18 21:02
●●●●●●●● ●●●●● ●●●●●●
Corcept Therapeutics announced that the CHMP has recommended EU approval for its ovarian cancer treatment, Relacorilant. The final decision from the European Commission is expected in the fourth quarter of 2026.…more
$86.29+0.45%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report